CHAIRES v. NOVO NORDISK INC.

CourtDistrict Court, D. New Jersey
DecidedDecember 17, 2021
Docket2:17-cv-00699
StatusUnknown

This text of CHAIRES v. NOVO NORDISK INC. (CHAIRES v. NOVO NORDISK INC.) is published on Counsel Stack Legal Research, covering District Court, D. New Jersey primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
CHAIRES v. NOVO NORDISK INC., (D.N.J. 2021).

Opinion

NOT FOR PUBLICATION

UNITED STATES DISTRICT COURT FOR THE DISTRICT OF NEW JERSEY

IN RE INSULIN PRICING LITIGATION Case No. 2:17-cv-00699 (BRM) (ESK)

OPINION

MARTINOTTI, DISTRICT JUDGE Before the Court is Defendants Novo Nordisk, Inc. (“Novo Nordisk”), Sanofi-Aventis U.S. LCC (“Sanofi”), and Eli Lilly and Company’s (“Eli Lilly”) (collectively, “Defendants”) Partial Motion to Dismiss the putative Plaintiffs’ (“Plaintiffs”) Third Amended Class Action Complaint (“Third Amended Complaint”) pursuant to Federal Rule of Civil Procedure 12(b)(6). (ECF No. 422.) Plaintiffs oppose the motion (ECF No. 455), and Defendants filed a reply (ECF No. 468). Having reviewed the parties’ submissions filed in connection with the Motion and having declined to hold oral argument pursuant to Federal Rule of Civil Procedure 78(b), for the reasons set forth below and for good cause having been shown, Defendants’ Partial Motion to Dismiss is GRANTED IN PART and DENIED IN PART. I. BACKGROUND1 For the purpose of this motion to dismiss, the Court accepts the factual allegations in the Third Amended Complaint as true and draws all inferences in the light most favorable to Plaintiffs.

1 The factual and procedural backgrounds of this matter are well-known to the parties and were previously recounted by the Court in its Opinion granting in part and denying in part Defendants’ Motion to Dismiss the First Amended Complaint (ECF No. 252), as well as the Court’s Opinion granting in part and denying in part Defendants’ Motion to Dismiss the Second Amended Complaint (ECF No. 304). Therefore, the Court includes only the facts and procedural background relevant to this Motion. See Phillips v. Cty. of Allegheny, 515 F.3d 224, 228 (3d Cir. 2008). The Court also considers any “document integral to or explicitly relied upon in the complaint.” In re Burlington Coat Factory Sec. Litig., 114 F.3d 1410, 1426 (3d Cir. 1997) (quoting Shaw v. Digit. Equip. Corp., 82 F.3d 1194, 1220 (1st Cir. 1996)).

Plaintiffs are 80 individuals who filed the Third Amended Complaint on behalf of themselves and a proposed nationwide class of analog insulin consumers. (ECF No. 411 ¶¶ 25–185.) Plaintiffs bring this action on behalf of themselves and all others similarly situated under Federal Rule of Civil Procedure 23(a) and 23(b)(3). (Id. ¶ 322.) Plaintiffs define their class as: All individual persons in the United States and its territories who paid any portion of the purchase price for a prescription of Apidra, Basaglar, Fiasp, Humalog, Lantus, Levemir, Novolog, Tresiba, and/or Toujeo at a price calculated by reference to a list price, AWP (Average Wholesale Price)2, or WAC (Wholesale Acquisition Price) for purposes other than resale.

(Id.) Specifically, the class includes uninsured consumers, consumers in high-deductible health plans, consumers who reach the Medicare Part D donut hole, and consumers with high coinsurance rates. (Id. ¶ 325.) Defendants are pharmaceutical companies headquartered in the United States. (Id. ¶¶ 186–88.) Defendants research, develop, and manufacture prescription medications. (Id.) Defendant Eli Lilly manufactures Humalog and Basaglar; Defendant Novo Nordisk manufactures Fiasp, Novolog, Levemir, and Tresiba; and Defendant Sanofi-Aventis manufactures Apidra, Lantus, and Toujeo. (Id.) On March 29, 2018, Plaintiffs filed the First Amended Class Action Complaint against Defendants (ECF No. 131), and on May 14, 2018, Defendants moved to dismiss (ECF No. 158).

2 The Plaintiffs frequently use the terms “benchmark price” and “sticker price” to refer to the AWP. (See, e.g., ECF No. 411 ¶¶ 2, 3, 202, 343.) In the First Amended Complaint, Plaintiffs brought claims under the federal Racketeer Influenced and Corrupt Organization Act (“RICO”) pursuant to 18 U.S.C. §§ 1961, et seq. (ECF No. 131.) The Court held oral argument on January 22, 2019. (ECF No. 247.) On February 15, 2019, the Court issued an Opinion and Order (the “February 2019 Order”) granting in part and denying in

part Defendants’ Motion to Dismiss the First Amended Class Action Complaint. (ECF Nos. 252– 53.) In the February 2019 Order, the Court dismissed Plaintiffs’ federal RICO claims, finding “[a]lthough Plaintiffs have adequately pled the various elements of a RICO claim,” they were indirect purchasers and, therefore, they “lack[ed] standing to maintain [the] action.” (ECF No. 252 at 25.) On March 18, 2019, Plaintiffs filed the Second Amended Class Action Complaint (“Second Amended Complaint”) alleging forty-nine counts against Defendants. (ECF No. 255.) In the Second Amended Complaint, Plaintiffs sought an injunction “to prevent [Defendants] from reporting benchmark prices that do not approximate their true net prices.” (Id. at 142.) Plaintiffs also included claims relating to additional insulin products not alleged in the First Amended

Complaint. (Compare ECF No. 131 with ECF No. 255.) Further, Plaintiffs included several state consumer protection law claims under the state laws of Arizona, California, Colorado, Georgia, Louisiana, Minnesota, Mississippi, Utah, Washington, and West Virginia. (ECF No. 225.) On May 17, 2019, Defendants filed a Partial Motion to Dismiss the Second Amended Complaint. (ECF No. 263.) Plaintiffs opposed the motion (ECF No. 269), and Defendants replied (ECF No. 273). On February 20, 2020, the Court issued an Opinion and Order (the “February 2020 Order”) granting in part and denying in part Defendants’ Motion to Dismiss the Second Amended Complaint. (ECF Nos. 304–05.) In the February 2020 Order, the Court held that a private party may not seek equitable relief under RICO and dismissed Plaintiffs’ request for injunctive relief under RICO. (ECF No. 304 at 7.) The Court also denied Defendants’ Partial Motion to Dismiss the claims related to the new insulin products, finding the Second Amended Complaint adequately alleged a detailed depiction of a fraudulent scheme as it related to the added insulin products. (Id. at 8.) The Court granted Defendants’ Partial Motion to Dismiss with respect to state consumer

protection law causes of action under the state laws of Arizona, Georgia, Mississippi, Washington, and West Virginia, but the Court denied Defendants’ Partial Motion to Dismiss with respect to state consumer protection law causes of action under the state laws of Colorado and Utah. (ECF No. 305 at 1.) The Court further granted Defendants’ Partial Motion to Dismiss to the extent that: (1) Plaintiffs sought disgorgement and restitution under California law; (2) Plaintiffs sought injunctive relief under Louisiana law; and (3) Plaintiff’s sought an award of monetary damages under Minnesota law. (Id. at 1–2.) On April 20, 2021, Plaintiffs filed the Third Amended Complaint, now alleging the following: violation of Arizona’s Civil Racketeering Statute, Ariz. Rev. Stat. §§ 13-2314.04, et seq., (Count Three); violation of Colorado’s Organized Crime Act, Colo. Rev. Stat. §§ 18-170-

101, et seq., (Count Four); violation of Florida’s Civil Remedies for Criminal Practices Act, Fla. Stat. Ann. §§ 772.101

Free access — add to your briefcase to read the full text and ask questions with AI

Related

West v. American Telephone & Telegraph Co.
311 U.S. 223 (Supreme Court, 1940)
Conley v. Gibson
355 U.S. 41 (Supreme Court, 1957)
Day & Zimmermann, Inc. v. Challoner
423 U.S. 3 (Supreme Court, 1975)
Illinois Brick Co. v. Illinois
431 U.S. 720 (Supreme Court, 1977)
United States v. Maine
469 U.S. 504 (Supreme Court, 1985)
Papasan v. Allain
478 U.S. 265 (Supreme Court, 1986)
Erickson v. Pardus
551 U.S. 89 (Supreme Court, 2007)
Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Shaw v. Digital Equipment Corp.
82 F.3d 1194 (First Circuit, 1996)
Robert H. Morast v. T. Bertram Lance
807 F.2d 926 (Eleventh Circuit, 1987)
McCARTHY v. RECORDEX SERVICE, INC.
80 F.3d 842 (Third Circuit, 1996)
In Re Rockefeller Center Properties, Inc.
184 F.3d 280 (Third Circuit, 1999)
Donald Boyanowski v. Capital Area Intermediate Unit
215 F.3d 396 (Third Circuit, 2000)

Cite This Page — Counsel Stack

Bluebook (online)
CHAIRES v. NOVO NORDISK INC., Counsel Stack Legal Research, https://law.counselstack.com/opinion/chaires-v-novo-nordisk-inc-njd-2021.